(ASND) Ascendis Pharma AS - Ratings and Ratios
Growth Hormone Therapy, Hypoparathyroidism Treatment, Oncology Therapeutics
ASND EPS (Earnings per Share)
ASND Revenue
Description: ASND Ascendis Pharma AS
Ascendis Pharma A/S is a biopharmaceutical company leveraging its proprietary TransCon technology to develop therapies addressing unmet medical needs across various regions including Europe, North America, and internationally. The company has a commercial presence with products such as SKYTROFA for pediatric growth hormone deficiency and YORVIPATH for adult chronic hypoparathyroidism.
The companys pipeline includes multiple endocrinology rare disease product candidates in clinical development, alongside a focus on advancing oncology therapeutic candidates, indicating a diversified approach to rare diseases and oncology. With a strong research and development foundation, Ascendis Pharma has established itself as a player in the biotechnology sector, particularly in the rare diseases and endocrinology spaces.
From a financial perspective, Ascendis Pharmas market capitalization stands at approximately $10.6 billion USD, with a Return on Equity (RoE) of 191.42%, indicating a highly efficient use of shareholder equity. The absence of a Price-to-Earnings (P/E) ratio suggests that the company is currently not profitable, which is common in the biotech industry due to significant R&D expenditures. Key Performance Indicators (KPIs) to watch include the progression of its pipeline candidates through clinical trials, commercial sales growth of SKYTROFA and YORVIPATH, and the expansion of its oncology portfolio.
To further assess the companys potential, investors should monitor the upcoming milestones for its product candidates, such as regulatory approvals, results from ongoing clinical trials, and any strategic partnerships or collaborations that could impact its financials and growth prospects. The companys ability to successfully commercialize its existing products and advance its pipeline will be crucial in driving future growth and enhancing shareholder value.
ASND Stock Overview
| Market Cap in USD | 12,287m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2015-01-28 |
ASND Stock Ratings
| Growth Rating | 67.9% |
| Fundamental | 32.2% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 19.0% |
| Analyst Rating | 4.75 of 5 |
ASND Dividends
Currently no dividends paidASND Growth Ratios
| Growth Correlation 3m | 79% |
| Growth Correlation 12m | 87% |
| Growth Correlation 5y | 9% |
| CAGR 5y | 23.72% |
| CAGR/Max DD 3y | 0.50 |
| CAGR/Mean DD 3y | 1.76 |
| Sharpe Ratio 12m | -0.39 |
| Alpha | 0.03 |
| Beta | 0.371 |
| Volatility | 45.09% |
| Current Volume | 254.7k |
| Average Volume 20d | 368.2k |
| Stop Loss | 192.2 (-3.7%) |
| Signal | 1.40 |
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income (-271.1m TTM) > 0 and > 6% of Revenue (6% = 29.4m TTM) |
| FCFTA -0.26 (>2.0%) and ΔFCFTA 35.87pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 31.18% (prev -69.39%; Δ 100.6pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.14 (>3.0%) and CFO -165.0m > Net Income -271.1m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 1.17 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (63.9m) change vs 12m ago 11.45% (target <= -2.0% for YES) |
| Gross Margin 84.88% (prev 85.56%; Δ -0.67pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 50.65% (prev 41.89%; Δ 8.76pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -3.57 (EBITDA TTM -150.9m / Interest Expense TTM 46.5m) >= 6 (WARN >= 3) |
Altman Z'' -9.73
| (A) 0.13 = (Total Current Assets 1.06b - Total Current Liabilities 907.9m) / Total Assets 1.18b |
| (B) -2.25 = Retained Earnings (Balance) -2.66b / Total Assets 1.18b |
| warn (B) unusual magnitude: -2.25 — check mapping/units |
| (C) -0.17 = EBIT TTM -166.0m / Avg Total Assets 968.9m |
| (D) -1.98 = Book Value of Equity -2.55b / Total Liabilities 1.29b |
| Total Rating: -9.73 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 32.16
| 1. Piotroski 1.0pt = -4.0 |
| 2. FCF Yield -2.86% = -1.43 |
| 3. FCF Margin -62.68% = -7.50 |
| 4. Debt/Equity data missing |
| 5. Debt/Ebitda -5.68 = -2.50 |
| 6. ROIC - WACC (= -30.73)% = -12.50 |
| 7. RoE data missing |
| 8. Rev. Trend 80.98% = 6.07 |
| 9. EPS Trend 80.39% = 4.02 |
What is the price of ASND shares?
Over the past week, the price has changed by -2.79%, over one month by +1.63%, over three months by +10.99% and over the past year by +41.32%.
Is Ascendis Pharma AS a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ASND is around 194.98 USD . This means that ASND is currently overvalued and has a potential downside of -2.31%.
Is ASND a buy, sell or hold?
- Strong Buy: 12
- Buy: 4
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ASND price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 249.9 | 25.2% |
| Analysts Target Price | 249.9 | 25.2% |
| ValueRay Target Price | 214.5 | 7.5% |
Last update: 2025-09-11 04:32
ASND Fundamental Data Overview
CCE Cash And Equivalents = 559.5m EUR (Cash And Short Term Investments, last fiscal year)
P/E Forward = 44.4444
P/S = 25.0369
P/B = 14.5547
Beta = 0.389
Revenue TTM = 490.7m EUR
EBIT TTM = -166.0m EUR
EBITDA TTM = -150.9m EUR
Long Term Debt = 365.1m EUR (from longTermDebt, last fiscal year)
Short Term Debt = 491.5m EUR (from shortTermDebt, last fiscal year)
Debt = 856.6m EUR (Calculated: Short Term 491.5m + Long Term 365.1m)
Net Debt = 297.1m EUR (from netDebt column, last fiscal year)
Enterprise Value = 10.77b EUR (10.47b + Debt 856.6m - CCE 559.5m)
Interest Coverage Ratio = -3.57 (Ebit TTM -166.0m / Interest Expense TTM 46.5m)
FCF Yield = -2.86% (FCF TTM -307.6m / Enterprise Value 10.77b)
FCF Margin = -62.68% (FCF TTM -307.6m / Revenue TTM 490.7m)
Net Margin = -55.25% (Net Income TTM -271.1m / Revenue TTM 490.7m)
Gross Margin = 84.88% ((Revenue TTM 490.7m - Cost of Revenue TTM 74.2m) / Revenue TTM)
Tobins Q-Ratio = -4.22 (set to none) (Enterprise Value 10.77b / Book Value Of Equity -2.55b)
Interest Expense / Debt = 3.85% (Interest Expense 33.0m / Debt 856.6m)
Taxrate = 21.0% (US default)
NOPAT = -166.0m (EBIT -166.0m, no tax applied on loss)
Current Ratio = 1.17 (Total Current Assets 1.06b / Total Current Liabilities 907.9m)
Debt / EBITDA = -5.68 (Net Debt 297.1m / EBITDA -150.9m)
Debt / FCF = -2.78 (Debt 856.6m / FCF TTM -307.6m)
Total Stockholder Equity = -178.5m (last 4 quarters mean)
RoA = -22.99% (Net Income -271.1m, Total Assets 1.18b )
RoE = unknown (Net Income TTM -271.1m / Total Stockholder Equity -178.5m)
RoCE = -88.95% (Ebit -166.0m / (Equity -178.5m + L.T.Debt 365.1m))
RoIC = -23.71% (NOPAT -166.0m / Invested Capital 699.9m)
WACC = 7.02% (E(10.47b)/V(11.33b) * Re(7.34%)) + (D(856.6m)/V(11.33b) * Rd(3.85%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 100.00 | Cagr: 1.24%
Discount Rate = 7.34% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
Fair Price DCF = unknown (Cash Flow -307.6m)
EPS Correlation: 80.39 | EPS CAGR: 61.44% | SUE: 1.25 | # QB: 1
Revenue Correlation: 80.98 | Revenue CAGR: 133.8% | SUE: N/A | # QB: None
Additional Sources for ASND Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle